Benzinga | Dec 7, 2021 07:02AM EST

Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $26

Mizuho analyst Vamil Divan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $24 to $26.